171 related articles for article (PubMed ID: 26701731)
1. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.
Izumi K; Mizokami A; Lin HP; Ho HM; Iwamoto H; Maolake A; Natsagdorj A; Kitagawa Y; Kadono Y; Miyamoto H; Huang CK; Namiki M; Lin WJ
Oncotarget; 2016 Feb; 7(7):8389-98. PubMed ID: 26701731
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study.
Iwamoto H; Izumi K; Nakagawa R; Toriumi R; Aoyama S; Shimada T; Kano H; Makino T; Kadomoto S; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Kadono Y; Mizokami A
Jpn J Clin Oncol; 2022 Nov; 52(11):1337-1344. PubMed ID: 35726158
[TBL] [Abstract][Full Text] [Related]
3. High coexpression of CCL2 and CX3CL1 is gender-specifically associated with good prognosis in soft tissue sarcoma patients.
Kehlen A; Greither T; Wach S; Nolte E; Kappler M; Bache M; Holzhausen HJ; Lautenschläger C; Göbel S; Würl P; Immel UD; Agaimy A; Wullich B; Taubert H
Int J Cancer; 2014 Nov; 135(9):2096-106. PubMed ID: 24676787
[TBL] [Abstract][Full Text] [Related]
4. Indole-3-carbinol and 3',3'-diindolylmethane modulate androgen's effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells.
Kim EK; Kim YS; Milner JA; Wang TT
Cancer Prev Res (Phila); 2013 Jun; 6(6):519-29. PubMed ID: 23585426
[TBL] [Abstract][Full Text] [Related]
5. Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer.
Izumi K; Shigehara K; Nohara T; Narimoto K; Kadono Y; Mizokami A
Anticancer Res; 2017 Oct; 37(10):5559-5564. PubMed ID: 28982870
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
7. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
Leach DA; Need EF; Toivanen R; Trotta AP; Palethorpe HM; Tamblyn DJ; Kopsaftis T; England GM; Smith E; Drew PA; Pinnock CB; Lee P; Holst J; Risbridger GP; Chopra S; DeFranco DB; Taylor RA; Buchanan G
Oncotarget; 2015 Jun; 6(18):16135-50. PubMed ID: 25965833
[TBL] [Abstract][Full Text] [Related]
8. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.
Zhang J; Lu Y; Pienta KJ
J Natl Cancer Inst; 2010 Apr; 102(8):522-8. PubMed ID: 20233997
[TBL] [Abstract][Full Text] [Related]
9. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
[TBL] [Abstract][Full Text] [Related]
10. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
[TBL] [Abstract][Full Text] [Related]
11. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
12. Real-Time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for the measurement of prostate-specific antigen mRNA in the peripheral blood of patients with prostate carcinoma using the taqman detection system.
Gelmini S; Tricarico C; Vona G; Livi L; Melina AD; Serni S; Cellai E; Magrini S; Villari D; Carini M; Serio M; Forti G; Pazzagli M; Orlando C
Clin Chem Lab Med; 2001 May; 39(5):385-91. PubMed ID: 11434386
[TBL] [Abstract][Full Text] [Related]
13. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
14. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
15. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
16. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.
Obinata D; Takada S; Takayama K; Urano T; Ito A; Ashikari D; Fujiwara K; Yamada Y; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Takahashi S; Inoue S
Eur J Cancer; 2016 Apr; 57():39-49. PubMed ID: 26854828
[TBL] [Abstract][Full Text] [Related]
17. Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner.
Lindemann C; Marschall V; Weigert A; Klingebiel T; Fulda S
Neoplasia; 2015 Jun; 17(6):481-9. PubMed ID: 26152356
[TBL] [Abstract][Full Text] [Related]
18. Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer.
Iwamoto H; Izumi K; Nakagawa R; Toriumi R; Aoyama S; Kamijima T; Shimada T; Kano H; Makino T; Naito R; Kadomoto S; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Kadono Y; Mizokami A
Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289628
[TBL] [Abstract][Full Text] [Related]
19. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
